A randomized clinical trial of regdanvimab in high-risk patients with mild-to-moderate coronavirus disease 2019
JY Kim, O Săndulescu, LL Preotescu… - Open forum …, 2022 - academic.oup.com
Background We evaluated clinical effectiveness of regdanvimab (CT-P59), a severe acute
respiratory syndrome coronavirus 2 neutralizing monoclonal antibody, in reducing disease …
respiratory syndrome coronavirus 2 neutralizing monoclonal antibody, in reducing disease …
A Randomized Clinical Trial of Regdanvimab in High-Risk Patients With Mild-to-Moderate Coronavirus Disease 2019.
JY Kim, O Săndulescu, LL Preotescu… - Open Forum …, 2022 - europepmc.org
Background We evaluated clinical effectiveness of regdanvimab (CT-P59), a severe acute
respiratory syndrome coronavirus 2 neutralizing monoclonal antibody, in reducing disease …
respiratory syndrome coronavirus 2 neutralizing monoclonal antibody, in reducing disease …
[PDF][PDF] A Randomized Clinical Trial of Regdanvimab in High-Risk Patients With Mild-to-Moderate Coronavirus Disease 2019
JY Kim, O Săndulescu, LL Preotescu… - 2022 - academia.edu
Background. We evaluated clinical effectiveness of regdanvimab (CT-P59), a severe acute
respiratory syndrome coronavirus 2 neutralizing monoclonal antibody, in reducing disease …
respiratory syndrome coronavirus 2 neutralizing monoclonal antibody, in reducing disease …
[HTML][HTML] A Randomized Clinical Trial of Regdanvimab in High-Risk Patients With Mild-to-Moderate Coronavirus Disease 2019
JY Kim, O Săndulescu, LL Preotescu… - Open Forum …, 2022 - ncbi.nlm.nih.gov
Background We evaluated clinical effectiveness of regdanvimab (CT-P59), a severe acute
respiratory syndrome coronavirus 2 neutralizing monoclonal antibody, in reducing disease …
respiratory syndrome coronavirus 2 neutralizing monoclonal antibody, in reducing disease …
A Randomized Clinical Trial of Regdanvimab in High-Risk Patients With Mild-to-Moderate Coronavirus Disease 2019
JY Kim, O Săndulescu, LL Preotescu… - Open forum …, 2022 - pubmed.ncbi.nlm.nih.gov
Background We evaluated clinical effectiveness of regdanvimab (CT-P59), a severe acute
respiratory syndrome coronavirus 2 neutralizing monoclonal antibody, in reducing disease …
respiratory syndrome coronavirus 2 neutralizing monoclonal antibody, in reducing disease …
A Randomized Clinical Trial of Regdanvimab in High-Risk Patients With Mild-to-Moderate Coronavirus Disease 2019.
JY Kim, O Sandulescu, LL Preotescu… - Open Forum Infectious …, 2022 - go.gale.com
Background. We evaluated clinical effectiveness of regdanvimab (CT-P59), a severe acute
respiratory syndrome coronavirus 2 neutralizing monoclonal antibody, in reducing disease …
respiratory syndrome coronavirus 2 neutralizing monoclonal antibody, in reducing disease …
A Randomized Clinical Trial of Regdanvimab in High-Risk Patients With Mild-to-Moderate Coronavirus Disease 2019
JY Kim, O Sandulescu, LL Preotescu… - 2022 - scholarworks.bwise.kr
Background We evaluated clinical effectiveness of regdanvimab (CT-P59), a severe acute
respiratory syndrome coronavirus 2 neutralizing monoclonal antibody, in reducing disease …
respiratory syndrome coronavirus 2 neutralizing monoclonal antibody, in reducing disease …
Randomized Clinical Trial of Regdanvimab in High-Risk Patients With Mild-to-Moderate Coronavirus Disease 2019.
JY Kim, O Săndulescu, LL Preotescu… - Open Forum …, 2022 - search.ebscohost.com
Background We evaluated clinical effectiveness of regdanvimab (CT-P59), a severe acute
respiratory syndrome coronavirus 2 neutralizing monoclonal antibody, in reducing disease …
respiratory syndrome coronavirus 2 neutralizing monoclonal antibody, in reducing disease …
[PDF][PDF] A Randomized Clinical Trial of Regdanvimab in High-Risk Patients With Mild-to-Moderate Coronavirus Disease 2019
JY Kim, O Săndulescu, LL Preotescu… - Open Forum …, 2022 - academic.oup.com
Background We evaluated clinical effectiveness of regdanvimab (CT-P59), a severe acute
respiratory syndrome coronavirus 2 neutralizing monoclonal antibody, in reducing disease …
respiratory syndrome coronavirus 2 neutralizing monoclonal antibody, in reducing disease …
A Randomized Clinical Trial of Regdanvimab in High-Risk Patients With Mild-to-Moderate Coronavirus Disease 2019
JY Kim, O Săndulescu, LL Preotescu… - Open forum …, 2022 - pubmed.ncbi.nlm.nih.gov
Background We evaluated clinical effectiveness of regdanvimab (CT-P59), a severe acute
respiratory syndrome coronavirus 2 neutralizing monoclonal antibody, in reducing disease …
respiratory syndrome coronavirus 2 neutralizing monoclonal antibody, in reducing disease …